Beneficial effects of raloxifene and atorvastatin on serum lipids and HDL phospholipids levels of postmenopausal women

Journal of Obstetrics and Gynaecology

Volumn 24, Issue 4, 2004, Pages 414-419

  Piperi, Christina ^a   Kalofoutis, C ^a   Skenderi, Katerina ^a   Economidou, Olga ^a   Kalofoutis, A ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; RALOXIFENE; SPHINGOMYELIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; PHOSPHOLIPID BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; REDUCTION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; POSTMENOPAUSE; PYRROLES; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME; TRIGLYCERIDES;

EID: 3042665553     PISSN: 01443615     EISSN: None     Source Type: Journal    
DOI: 10.1080/01443610410001685565     Document Type: Article

References (32)

1. Agnusdei D., Liu-Leage S. and Augendre-Ferrante B. (1999) Results of international clinical trials with raloxifene. Annals of Endocrinology, 60, 242-246.
2. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J. and Schaefer E.J. (2002a) Comparing the effects of five different statins on the HDL subpopulation profiles of coronary heart disease patients. Atherosclerosis, 164, 361-369.
3. Asztalos B.F., Horvath K.V., McNamara J.R., Roheim P.S., Rubinstein J.J. and Schaefer E.J. (2002b) Effects of atorvastatin on the HDL subpopulation profile of coronary heart disease patients. Journal of Lipid Research, 43, 1701-1707.
4. Boyack M., Lookinland S. and Chasson S. (2002) Efficacy of raloxifene for treatment of menopause: a systematic review. Journal of the American Academy of Nurse Practice, 14, 150-165.
5. Bryant H.U. and Dere W.H. (1998) Selective estrogen receptor modulators: an alternative to hormone replacement therapy. Proccedings of the Society of Experimental Biology and Medicine, 217, 45-52.
6. Colditz G.A., Willett W.C., Stampfer M.J., Rosner B.S., Speizer F.E. and Hennekens C.H. (1987) Menopause and the risk of coronary heart disease in women. New England Journal of Medicine, 316, 1105-1110.
7. Downs J.R., Clearfield M., Weis S., Whitney E., Shapiro D.R., Beere P.A., Langendorfer A., Stein E.A., Kruyer W. and Gotto A.M. Jr. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. Journal of the American Medical Association, 279, 1615-1622.
8. Draper M.W., Flowers D.E., Huster W.J. and Neild J.A. (1993) Effects of raloxifene (LY139481) HCl on biochemical markers of bone and lipid metabolism in healthy post-menopausal women. In: Proceedings of the Fourth International Symposium on Osteoporosis and Consensus Development Conference, edited by Christiansen C. and Riis B, pp. 119-121. Aalborg, Denmark, Handelstrykkeriet Aalborg ApS.
9. Draper M.W., Flowers D.E., Huster W.J., Neild J.A., Harper K.D. and Arnaud C.A. (1996) Controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. Journal of Bone and Mineral Research, 11, 835-842.
10. Friedewald W.T., Levy R.I. and Fredrickson S. (1972) Estimation of the concentration of the low density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clinical Chemistry, 18, 499-502.
11. Giral P., Bruckert E., Jacob N., Chapman M.J., Foglietti M.J. and Turpin G. (2001) Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis, 154, 421-427.
12. Gonbert S., Malinsky S., Sposito A.C., Laouenan H., Doucet C., Chapman M.J. and Thillet J. (2002) Atorvastatin lowers lipoprotein(a) but not apolipoprotein(a) fragment levels in hypercholesterolemic subjects at high cardiovascular risk. Atherosclerosis, 164, 305-311.
13. Hunninghake D., Insull W. Jr, Toth P., Davidson D., Donovan J.M. and Burke S.K. (2001a) Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively. Atherosclerosis, 158, 407-416.
14. Hunninghake D., Insull W., Knopp R., Davidson M., Lohrbauer L., Jones P. and Kafonek S. (2001b) Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. American Journal of Cardiology, 88, 635-639.
15. Insull W., Kafonek S., Goldner D. and Zieve F. (2001) Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks. ASSET Investigators. American Journal of Cardiology, 87, 554-559.
16. Kakafika A., Liamis G., Elisaf M. and Mikhailidis D. (2001b) Effect of atorvastatin on serum creatinine levels. Current Medical Research Opinion, 17, 230-231.
17. Kakafika A., Tsimihodimos V. and Elisaf M. (2001a) Effect of atorvastatin on serum uric acid levels. Atherosclerosis, 158, 255.
18. Kannel W.B., Hjortland M.C., Mc Namara P.M. and Gordon T. (1976) Menopause and risk of cardiovascular disease. The Framingham Study. Annals of Internal Medicine, 85, 447-452.
19. Kauffman R.F. and Bryant H.U. (1995) Selective estrogen receptor modulators. Drugs New Perspectives, 8, 531-539.
20. Lufkin E.G., Whitaker M.D., Nickelsen T., Argueta R., Caplan R.H., Knickerbocker R.K. and Riggs B.L. (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. Journal of Bone and Mineral Research, 13, 1747-1754.
21. Nikolaidou-Politis V., Papapanagiotou A. and Kalofoutis A. (1999) Effects of hormone replacement therapy on serum lipids and phospholipids in postmenopausal women. Journal of Obstetrics and Gynecology, 19, 184-189.
22. Paolisso G., Barbagallo M., Petrella G., Ragno E., Barbieri M., Giordano M. and Varricchio M. (2000) Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis, 150, 121-127.
23. Park L. and Evans M.F. (1999) Raloxifene: designer estrogen for preventing postmenopausal osteoporosis. Canadian Family Physician, 45, 1191-1193.
24. Pedersen T.R., Olsson A.C., Faergeman O., Kjekshus J., Wedel H., Berg K., Wilhelmsen L., Haghfelt T., Thorgeirsson G., Pyorala K., Miettinen T., Christophersen B., Tobert J.A., Musliner T.A. and Cook T.J. (1998) Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation, 97, 1453-1460.
25. Rosenson R.S. and Tangney C.C. (1998) Anti-atherothrombotic properties of statins: implications for cardiovascular event reduction. Journal of the American Medical Association, 279, 1643-1650.
26. Sacks F.M., Pfeffer M.A., Moye L.A., Rouleau J.L., Rutherford J.D., Cole T.G., Brown L., Warnica J.W., Arnold J.M., Wun C.C., Davis B.R. and Braunwald E. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. New England Journal of Medicine, 335, 1001-1009.
27. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., McKillop J.H. and Packard C.J. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. New England Journal of Medicine, 333, 1301-1307.
28. Tutor J.C., Paz J.M., Areses J. and Garcia F. (1981) Determination of high density phospholipids and its possible clinical application in the assessment of cardiovascular disease risk. Biometrica, 12, 65-69.
29. Umland E.M., Rinaldi C., Parks S.M. and Boyce E.G. (1999) The impact of estrogen replacement therapy and raloxifene on osteoporosis, cardiovascular disease, and gynecologic cancers. Annals of Pharmacotherapy, 33, 1315-1328.
30. Walsh B.W., Kuller L.H., Wild R.A., Paul S., Farmer M., Lawrence J.B., Shah A.S. and Anderson P.W. (1998) Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. Journal of the American Medical Association, 279, 1445-1451.
31. Yamaguchi Y. (1980) Determination of high-density lipoprotein phospholipids in serum. Clinica Chimica Acta, 26, 1275-1277.
32. Yang N.N., Venugopalan M., Hardikar S. and Glasebrook A. (1996) Identification of an oestrogen response element activated by metabolites of 17b-estradiol and raloxifene. Science, 273, 1222-1225.